Why did Unicycive's operating expenses surge in Q2 2024?

Unicycive's operating expenses did not surge in Q2 2024. In fact, the company's financial results for Q2 2024 showed no licensing revenues recorded, and the company was on track to provide top-line data from its ongoing pivotal clinical trial with Oxylanthanum Carbonate (OLC) in Q2 2024. The company's focus was on advancing its clinical trials rather than increasing operating expenses.